<DOC>
	<DOCNO>NCT01309646</DOCNO>
	<brief_summary>This study design evaluate safety immunogenicity Infanrix™-IPV+Hib vaccine administer primary vaccination course healthy Korean infant 2 , 4 6 month age .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline Biologicals ' Infanrix™-IPV+Hib Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female , include , 42 69 day age time first vaccination . Born gestation period 37 42 week inclusive . Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . Written inform consent obtain parent ( ) / Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Administration vaccine foreseen study protocol , within 30 day prior first study visit , exception hepatitis B Bacillus CalmetteGuérin vaccination ; plan administration study period , exception hepatitis B influenza vaccine , allow least 7 day 30 day administration DTPa vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , poliomyelitis Hib vaccination disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurological disorder seizure . Administration immunoglobulins and/or blood product since birth plan administration study period . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>69 Days</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary vaccination</keyword>
	<keyword>combination vaccine</keyword>
	<keyword>South Korea</keyword>
</DOC>